Theriva Biologics, Inc.
TOVX- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000894158
No open-market purchases or sales by Theriva Biologics, Inc. insiders were filed in the last 90 days; 26 institutions reported holding it in 13F filings for Q2 2026, worth $495.5K in total; no superinvestor holds it.
13F holders, Q1 2026
Institutional positions in Theriva Biologics, Inc. as of Mar 31, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 22
- +2 vs. Q4 2025
- Shares held
- 1.97M
- +925.5K (+89.0%) vs. Q4 2025
- Total value
- $385.4K
- +$166.7K (+76.2%) vs. Q4 2025
- New holders
- 5
- 5 more added
- Sold out
- 3
- 5 more reduced
1 institution that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TOVX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 26 | $495.5K |
| Q1 2026 | 22 | $385.4K |
| Q4 2025 | 21 | $272.4K |
| Q3 2025 | 20 | $177.0K |
| Q2 2025 | 17 | $126.3K |
| Q1 2025 | 11 | $209.8K |
| Q4 2024 | 10 | $60.3K |
| Q3 2024 | 18 | $678.6K |
| Q2 2024 | 22 | $327.6K |
| Q1 2024 | 24 | $366.3K |
| Q4 2023 | 24 | $452.3K |
| Q3 2023 | 21 | $572.8K |
| Q2 2023 | 18 | $1.01M |
| Q1 2023 | 19 | $724.6K |
| Q4 2022 | 22 | $477.1K |
| Q3 2022 | 26 | $1.15M |
| Q2 2022 | 33 | $2.51M |
| Q1 2022 | 35 | $3.17M |
| Q4 2021 | 35 | $3.24M |
| Q3 2021 | 36 | $3.32M |
| Q2 2021 | 31 | $3.91M |
| Q1 2021 | 32 | $5.80M |
Institutions, Q1 2026
Shares, value and share of portfolio for each institution holding Theriva Biologics, Inc.; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Geode Capital Management, LLC | 450,263 | $88.2K | 0.00% | +238,176+112.3% | Added |
| Virtu Financial LLC | 253,218 | $50.0K | 0.00% | +253,218 | New |
| Vanguard Fiduciary Trust Co | 241,780 | $47.4K | 0.00% | +241,780 | New |
| UBS Group AG | 225,624 | $44.2K | 0.00% | +34,214+17.9% | Added |
| Vanguard Capital Management LLC | 192,404 | $37.7K | 0.00% | +192,404 | New |
| Jane Street Group, LLC | 177,034 | $34.7K | 0.00% | +177,034 | New |
| Ikarian Capital, LLC | 112,076 | $21.9K | 0.00% | 00.0% | Unchanged |
| Two Sigma Securities, LLC | 105,241 | $20.6K | 0.00% | +62,348+145.4% | Added |
| XTX Topco Ltd | 94,620 | $18.5K | 0.00% | +55,175+139.9% | Added |
| Boothbay Fund Management, LLC | 27,646 | $5.41K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 23,602 | $4.62K | 0.00% | −176,398−88.2% | Reduced |
| StoneX Group Inc. | 22,280 | $4.36K | 0.00% | −14,937−40.1% | Reduced |
| Two Sigma Investments, LP | 15,441 | $3.02K | 0.00% | −26,896−63.5% | Reduced |
| Schwarz Dygos Wheeler Investment Advisors LLC | 15,000 | $2.94K | 0.00% | 00.0% | Unchanged |
| BlackRock, Inc. | 7,504 | $1.47K | 0.00% | 00.0% | Unchanged |
| Citigroup Inc | 1,391 | $272 | 0.00% | −4,798−77.5% | Reduced |
| SBI Securities Co., Ltd. | 131 | $26 | 0.00% | +72+122.0% | Added |
| IFP Advisors, Inc | 11 | $2 | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 8 | $1 | 0.00% | −440−98.2% | Reduced |
| Newbridge Financial Services Group, Inc. | 5 | $1 | 0.00% | 00.0% | Unchanged |
| Danske Bank A/S | 1 | $0 | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 1 | $0 | 0.00% | +1 | New |
| DRW Securities, LLC | 0 | $0 | 0.00% | −41,745−100.0% | Sold out |
| Barclays PLC | 0 | $0 | 0.00% | −32,569−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −31,139−100.0% | Sold out |
| Vanguard Group Inc | – | – | – | – | Not filed |